Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-Blind, Randomized, Parallel-Group Study to Evaluate Long-Term Safety, Tolerability, and Efficacy of a Fixed Dose Combination GSP 301 Nasal Spray Compared With Two Placebo Nasal Spray Formulations in Subjects (Aged 12 Years and Older) With Perennial Allergic Rhinitis (PAR)

Next Previous
Trial Profile

A Double-Blind, Randomized, Parallel-Group Study to Evaluate Long-Term Safety, Tolerability, and Efficacy of a Fixed Dose Combination GSP 301 Nasal Spray Compared With Two Placebo Nasal Spray Formulations in Subjects (Aged 12 Years and Older) With Perennial Allergic Rhinitis (PAR)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 28 Feb 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mometasone/olopatadine (Primary)
  • Indications Perennial allergic rhinitis
  • Focus Adverse reactions; Registrational
  • Sponsors Glenmark Pharmaceuticals S.A.

Most Recent Events

  • 26 Feb 2020 According to a Hikma Pharmaceuticals media release, the FDA issued a Complete Response Letter (CRL) to Glenmark regarding the NDA for Ryaltris in June 2019, citing deficiencies pertaining to the proposed manufacturing facility.The CRL did not specify any deficiencies with the clinical data supporting the NDA for Ryaltris.
  • 15 Nov 2018 According to a Glenmark Pharmaceuticals media release, the companys NDA for Ryaltris is under review with U.S. FDA and the Prescription Drug User Fee Act (PDUFA) target action date for completion of the FDA review is 21 Mar 2019.
  • 15 Nov 2018 According to a Glenmark Pharmaceuticals media release, long term safety and efficacy data from this trial will be presented at the American College of Allergy, Asthma and Immunology Annual Scientific Meeting 2018 (ACAAI 2018) (Seattle, Washington).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top